EGFR and neoplasm: By using KCI-10-40X1, a PDX model derived from a GBM patient with EGFRamp, we found that a combination of V-4084 and erlotinib inhibited KCI-10-X1/erl-res tumor growth and provide additional evidence to treat GBM EGFRamp patients targeting both EGFR and MET.